US FDA's expedited access plan for devices a 'program with no downside'?
This article was originally published in SRA
Executive Summary
Stakeholders appear unanimous in their support of a new plan by the US Food and Drug Administration to fast-track certain high-risk, high-value medical devices through the premarket approval (PMA) program.